Vir Biotechnology, Inc. has announced that they will discuss initial data from Phase 1 clinical studies regarding their dual masked T-cell engagers, VIR-5818 and VIR-5500, targeting various solid tumors and metastatic castration-resistant prostate cancer respectively. The discussion will take place during a virtual investor event scheduled for January 8, 2025, with a live webcast available on their investor relations website. Moreover, a clerical error involving a missing electronic signature from Ernst & Young on the Consent document filed in their 2023 Form 10-K has been rectified and properly signed Consent is now included as an exhibit.
Proper names mentioned: - Vir Biotechnology, Inc. - Ernst & Young - Marianne De Backer